Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors

Abstract

The use of coxibs and spending on NSAIDs varies widely by state and declined substantially after the implementation of prior-authorization programs. Determining whether these reductions are clinically appropriate will have important implications for the development of rational drug-reimbursement policies.